Sitagliptine (Januvia®): Incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes;Le médicament du mois - Sitagliptine (Januvia®) Incrétinopotentiateur indiqué comme insulinosécré tagogue dans le traitement du diabète de type 2

Revue Medicale de Liege

Volumn 63, Issue 2, 2008, Pages 105-109

  Scheen, A J ^a,b   Van Gaal, L F ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

^c Hôpital Universitaire d'Anvers

Author keywords

Dipeptidylpeptidase 4 inhibitor; Glucagon like peptide 1; Incretin; Insulin secretion; Sitagliptin; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HORMONE; INCRETIN; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA;

ARTICLE; BLOOD GLUCOSE MONITORING; DIABETIC PATIENT; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN RELEASE; L CELL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

BELGIUM; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; PYRAZINES; TRIAZOLES;

EID: 41149112991     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Scheen AJ, Lefèbvre PJ. - Insulin resistance vs. insulin deficiency : which comes first ? The old question revisited. In : Diabetes in the New Millennium ( Eds : Di Mario U, Leonetti F, Pugliese G, et al), J. Wiley & Sons, New York, 2000, 101-113.
2. Scheen AJ, Radermecker RP, Philips JC, et al. - Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège, 2007, 62, (Suppl), 40-46.
3. Nathan DM, Buse JB, Davidson MB, et al. - Management of hyperglycaemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2006, 49, 1711-1721.
4. Scheen AJ. - Pathophysiology of insulin secretion. Ann Endocrinol, 2004, 65, 29-36.
5. Radermecker RP. - Place des insulinosécrétagogues dans le traitement du diabète de type 2. Rev Med Liège, 2005, 60, 402-408.
6. Krentz AJ, Bailey CJ. - Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs, 2005, 65, 385-411.
7. Scheen AJ. - Les sulfamidés hypoglycémiants, 50 ans après Loubatières. Rev Med Liège, 1996, 51, 90-93.
8. Radermecker RP. - Le risque hypoglycémique chez le patient diabétique : implications thérapeutiques. Rev Med Liège, 2005, 60, 461-465.
9. Scheen AJ. - Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liège, 2002, 57, 352-356.
10. Drucker DJ, Nauck MA. - The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
11. Scheen AJ, Radermecker RP, Philips JC, Paquot N. - Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse, 2007, 3, 1884-1888.
12. Scheen AJ. - Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabète de type 2. Rev Med Liège, 2007, 62, 216-219.
13. Idris I, Donnelly R. - Dipeptidyl peptidase-IV inhibitors : a major new class of oral antidiabetic drug. Diab Obes Metab, 2007, 9, 153-165.
14. Lyseng-Williamson KA. - Sitagliptin. Drugs, 2007, 67, 587-597.
15. Aschner P, Kipnes M, Lunceford J, et al. - Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 2006, 29, 2632-2637.
16. Raz I, Hanefeld M, Xu L, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 2006, 49, 2564-2571.
17. Charbonnel B, Karasik A, Liu J, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 2006, 29, 2638-2643.
18. Hermansen K, Kipnes M, Luo E, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diab Obes Metab, 2007, 9, 733-745.
19. Rosenstock J, Brazg R, Andryuk PJ, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo controlled, parallel-group study. Clin Ther, 2006, 28, 1556-1568.
20. Nauck M, Meiniger G, Sheng D, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diab Obes Metab, 2007, 9, 194-205.
21. American Diabetes Association. - Standards of medical care in diabetes - 2008. Diabetes Care, 2008, 31, S12-54.